Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides

A technology of natriuretic peptide and eye drops, which is applied in the field of natriuretic peptide eye drops, can solve the problems of little research on α-ANP and no report on the effect of natriuretic peptide

Inactive Publication Date: 2004-10-06
SANTEN PHARMA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, other effects of α-ANP have been rarely studied, and the literature does not report the effects of natriuretic peptides on lacrimal and keratoconjunctival disorders (by instilling them)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment

[0017] A typical formulation is as follows:

[0018] Formulation 1 (preparation of 0.1% eye drops)

[0019] 0.1% eye drops were prepared by dissolving natriuretic peptide (100 mg) in physiological saline (100 ml).

[0020] In addition, natriuretic peptide eye drops at concentrations of 0.001%, 0.005%, 0.01%, 0.05%, 0.5% and 1.0% (W / V) were also prepared by varying the amount of natriuretic peptide added.

[0021] 2. Pharmacological test

[0022] The Schirmer test paper method (which is used to measure tear volume in humans) is a method for measuring changes in tear volume in normal animals when drugs are instilled. In the present invention, the amount of tear fluid when natriuretic peptide was instilled was measured by applying the Schirmer test paper method, and the effect of natriuretic peptide on the tear fluid secretion rate was studied.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The object of the present invention is to find new effects of natriuretic peptides in an ophthalmological field. The present invention provides eyedrops for promoting lacrimal secretion or for treating keratoconjunctival disorders containing the natriuretic peptide as active ingredient. The natriuretic peptides are atrial natriuretic peptides (ANP), brain natriuretic peptides (BNP) and C-type natriuretic peptides (CNP). Typical examples of the keratoconjunctival disorder are dry eye, corneal erosion and corneal ulcer.

Description

technical field [0001] The present invention relates to an eye drop comprising natriuretic peptide as an active ingredient for promoting tear secretion or treating keratoconjunctival disorders. Background technique [0002] Tears (which in organisms have a mechanism for maintaining moisture) cover the cornea and conjunctiva (keratoconjunctiva), retaining moisture and preventing them from drying out. Tears act as lubricants (ie, protect the corneal conjunctiva from the irritation of blinking) and help keep the corneal surface smooth. Tears have an antibacterial effect, prevent infection by bacteria, fungi, viruses, etc., provide oxygen and various nutrients to the cornea and remove carbon dioxide gas and metabolites. When the keratoconjunctiva is abnormal, tears serve to dilute and remove the stimuli that caused the disorder, as well as to carry fluid components (eg, epithelial growth factor involved in wound healing) and blood cell components (eg, fibronectin) to the abnor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/22A61P27/02
CPCA61K38/2242A61P27/02A61K38/02
Inventor 中田胜彦中村雅胤
Owner SANTEN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap